An observational study in Immune Response To Sepsis and Staphylococcus Aureus Infection, sponsored by University of Chicago. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by University of Chicago · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Staphylococcal Infections with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Staphylococcal Infections · United States.
Among the 125 studies in Staphylococcal Infections with a site in United States, this one is the 23rd largest by enrollment of the 32 observational ones that give a count, is one of 8 that started in 2013, is one of 33 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 78th registered.
305 studies on the registry are indexed under Staphylococcal Infections; 36 are open to participants now.
Browse Staphylococcal Infections studies →6 of the 125 studies in Staphylococcal Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–120
Johns Hopkins University · Sites in United States
Ages 0–60 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18–65
University of Melbourne · Sites in United States, Australia, Canada and 10 more countries
Texas Woman's University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Staphylococcal Infections studies recruiting now, 16 (73%) set no upper age limit and 4 (18%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 26 · Phase 3 15 · Phase 4 16
First in 2000; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is below the median of 190 across 91 observational studies indexed under Staphylococcal Infections.
Median enrollment 158 across the 92 interventional studies, 217 across the 32 observational. Of the 105 that completed or were terminated, 44 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 125 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 1 study filed under Staphylococcal Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Staphylococcal Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06749457AstraZenecaA Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) | 2027-03-08 |
| NCT01879761University of ChicagoImmune Resolution After Staphylococcus Aureus Bacteremia | 2027-06 |
| NCT06805994Johns Hopkins UniversityAdministering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies in Staphylococcal Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.
Hospital inpatients with Staphylococcus aureus bacteremia who are over 18 years old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are:
Exclusion Criteria:
Immunosuppressed includes patients with any one of the following: 1. a diagnosis of a hematological malignancy 2. a diagnosis of HIV 3. myelosuppressive chemotherapy in the previous 90 days 4. immune-modulating medications in the previous 90 days
Subject does not fit immunosuppressed criteria
HLA-DR and cytokines
Percent expression of HLA-DR on monocytes will be measured by flow cytometry. Cytokine levels will be measured by ELISA.
Time frame: 0-30 days
New Infections
Time frame: 0-90 days
Mortality
Time frame: 0-90 days
The record gives a start of Jun 2013, a primary completion of Jun 2027 and a completion of Jun 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.